Mesa Laboratories (MLAB) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLAB shares.
View MLAB analyst ratings or view top-rated stocks.

1 brokers have issued 1 year target prices for Mesa Laboratories' shares. Their MLAB share price targets range from $130.00 to $130.00. On average, they predict the company's stock price to reach $130.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for MLAB or view top-rated stocks among Wall Street analysts.

Mesa Laboratories' stock was trading at $104.77 at the start of the year. Since then, MLAB stock has decreased by 3.5% and is now trading at $101.14.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 24th 2024.
View our MLAB earnings forecast.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its quarterly earnings data on Monday, February, 5th. The medical instruments supplier reported $1.46 earnings per share for the quarter, missing analysts' consensus estimates of $1.47 by $0.01. The medical instruments supplier had revenue of $53.47 million for the quarter, compared to the consensus estimate of $54.90 million. Mesa Laboratories had a trailing twelve-month return on equity of 7.41% and a net margin of 0.45%.

Mesa Laboratories announced a quarterly dividend on Tuesday, April 2nd. Stockholders of record on Friday, May 31st will be paid a dividend of $0.16 per share on Friday, June 14th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Friday, May 31st.
Read our dividend analysis for MLAB.

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.61%. The dividend payout ratio is 376.49%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 8.90% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MLAB.

ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include Motley Fool Small-Cap Growth ETF (TMFS).MFAM Small-Cap Growth ETF (MFMS).

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and Company (BDX).

Mesa Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.10%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall.
View institutional ownership trends.

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.